A MESSAGE FROM DR MARY KAN
Published on Monday, 01 July 2024
Dear Singapore Biodesign Partners and Friends,
As of 1st April 2024, I have transitioned out of my role as Programme Director at Singapore Biodesign (SB). Stepping up to take on the role of Acting Programme Director will be Dr Lee Phin Peng, who was serving as SB's Deputy Programme Director.
During my tenure at SB, I had the privilege of leading the program through significant transformation from Singapore-Stanford Biodesign to Singapore Biodesign, securing continued funding for the programme, driving the development of the Health and MedTech Innovation Training White Paper, and implementing quality transformation initiatives like curriculum professionalization and high-quality training programmes. My dedication to fostering valuable industry connections resulted in robust relationships with local, regional, and international partners. These collaborations supported various initiatives, including the Innovation Fellowship, Faculty Fellowship, A*STAR GAP Champion Development Scheme, BOLT Initiative, regional clinical immersion, and many others.
Dr. Lee Phin Peng has been an invaluable member of SB since joining in 2020, playing a significant role in securing RIE2025 funding and driving the implementation of strategic initiatives. His contributions have been instrumental in scaling up SB's training programmes and introducing Design Thinking courses to A*STAR. As we welcome Phin to helm SB leadership, I have full confidence in his capabilities to lead SB forward, and I'm excited to see the program continue to grow and make an impact under his guidance.
Once again, I would like to offer my sincere thanks to everyone for their unwavering support to SB and our alumni over the years. I trust that you will continue to extend the same support to Phin as the new Programme Director of Singapore Biodesign. Thank you.
Dr Lee Phin Peng
.png?sfvrsn=606c8304_1 "Untitled design (53)")
Dr. Lee Phin Peng is a health and medical technology executive experienced with developing and driving innovation programmes at the national level. He is concurrently serving as the Acting Programme Director (Effective April 1, 2024) for Singapore Biodesign and Lead at the Medtech Control Tower, I&E, A*STAR. Dr Lee also holds an adjunct Assistant Professor position at the Duke-NUS Medical School.
Prior to his current role, Dr. Lee was a Principal Investigator for a medical technology project around cerebrovascular stroke monitoring and detection. He served in a joint appointment at the Institute of Materials Research and Engineering and the Institute of High Performance Computing at the Agency for Science, Technology and Research (A*STAR) Singapore. Dr. Lee’s publications in peer-reviewed journals have been cited more than 700 times.
Dr. Lee is an experienced speaker who has been invited to speak at numerous events, speaker panels and conferences. He is also an accomplished and certified adult educator – Dr. Lee has trained more than 600 researchers, healthcare professionals, and corporates in Design Thinking and the Biodesign methodology.
Dr. Lee holds a PhD in Bioengineering from the University of California, San Francisco – Berkeley and a BSc in Biomedical Engineering from Brown University. He completed his post-doctoral training at the Stanford School of Medicine under the Singapore-Stanford Biodesign Innovation Fellowship.
A*STAR celebrates International Women's Day
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.
Get inspired by our #WomeninSTEM